tcsc0295 Nutlin (3)

Nutlin 3 is a commercial available p53-MDM2 inhibitor, with K_i of 90 nM.

IC50 & Target: Ki: 90 nM (p53-MDM2)^[1]

In Vitro: Nutlin 3 is an inhibitor of the MDM2-p53 interaction. In particular, co-treatment of p53-positive HCT116 cells with 1 μM of Inauhzin and 2 μM of Nutlin 3 more significantly activated p53 as measured by its protein level as well as the level of its target p21, PUMA or cleaved PARP as indication of apoptosis^[2]. Nutlin 3 is a small-molecule inhibitor that acts to inhibit MDM2 binding to p53 and subsequent p53-dependent DNA damage signaling. As a single agent, Nutlin 3 (2-10 μM) stabilizes p53 and p21^WAF levels and is toxic to WTp53-22RV1 cells (IC₅₀, 4.3 μM) but has minimal toxicity toward p53-deficient cells (IC₅₀, >10 μM). Nutlin 3 induces p53 and p21^WAF expression in a dose-dependent manner in 22RV1 cells. Short-term cell cycle assays show that, at a dose of 10 μM, Nutlin 3 increasea slightly the G₁-phase fraction and decreasea S-phase fraction of all three cell lines^[3].



In Vivo: Nutlin 3 can suppress the growth of xenograft tumors derived from human osteosarcoma or leukemia cells, the anti-tumor activity of Nutlin 3 even at the dose of 200 mg/kg per oral administration is marginal in an HCT116-derived xenograft tumor model^[2]. Nutlin 3 may be a useful adjunct to improve the therapeutic ratio using precision radiotherapy targeted to hypoxic cells and warrants further study in vivo^[3].